Xenetic Biosciences
XBIO
Market cap $6.97M

4.52 USD

-0.01

0.22%

At close Oct 4, 4:00 PM EDT

1 day

-0.22%

5 days

18.02%

1 month

10.51%

3 months

12.72%

6 months

2.73%

Year to date

26.61%

1 year

3.91%

5 years

-57.76%

About: Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.

Employees: 4

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0.31% less ownership

Funds ownership: 1.27% [Q1] → 0.97% (-0.31%) [Q2]

16% less capital invested

Capital invested by funds: $73.8K [Q1] → $62K (-$11.7K) [Q2]

29% less funds holding

Funds holding: 7 [Q1] → 5 (-2) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for XBIO.

See Analyst Rankings

Financial journalist opinion

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jim Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, presented at the H.C. Wainwright 26 th Annual Global Investment Conference.

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Ongoing preclinical studies with data expected before year end Focus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indications Ended the quarter with $7.3 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / August 14, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2024. "We remain confident in the potential of our DNase-based oncology platform and continue to advance our preclinical studies with data expected before year end.

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Zacks Investment Research

Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates

Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.83 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.69 per share a year ago.

Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the quarter with $7.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / May 10, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2024 and provided a business update. "We have initiated several preclinical studies on the influence of DNase in combination with standard treatment paradigms such as chemotherapy or immune checkpoint blockade and expect to present results in the second half of this year.

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Zacks Investment Research

Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.60 per share a year ago.

Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the year ended December 31, 2023. Recent Highlights Entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of the DNase program.

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of its systemic DNase program. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps ("NETs"), which are weblike structures composed of extracellular chromatin coated with histones and other proteins.

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

See News Rankings

Charts implemented using Lightweight Charts™